 | • レポートコード：MRC2303I0177 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、105ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査レポートでは、世界の破傷風トキソイドワクチン市場規模が、予測期間中（2022年-2027年）に年平均4.8%で成長すると予測しています。本書では、破傷風トキソイドワクチンの世界市場について調べ、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、ワクチン種類別（DTaP、DT、Tdap、その他）分析、エンドユーザー別（病院&診療所、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、南米、中東・アフリカ、アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、その他）分析、競争状況、市場機会・将来の動向など、以下の構成でまとめております。また、Merck & Co. Inc、GlaxoSmithKline Plc、Sanofi （Sanofi Pasteur Inc.）、Pfizer Inc.、Bharat Biotech、Astellas Pharma Inc.、Panacea Biotec Ltd、BB - NCIPD Ltd、PT Bio Farma、Biological E Limitedなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の破傷風トキソイドワクチン市場規模：ワクチン種類別 - DTaPの市場規模 - DTの市場規模 - Tdapの市場規模 - その他ワクチンの市場規模 ・世界の破傷風トキソイドワクチン市場規模：エンドユーザー別 - 病院&診療所における市場規模 - その他エンドユーザーにおける市場規模 ・世界の破傷風トキソイドワクチン市場規模：地域別 - 北米の破傷風トキソイドワクチン市場規模 アメリカの破傷風トキソイドワクチン市場規模 カナダの破傷風トキソイドワクチン市場規模 メキシコの破傷風トキソイドワクチン市場規模 … - ヨーロッパの破傷風トキソイドワクチン市場規模 ドイツの破傷風トキソイドワクチン市場規模 イギリスの破傷風トキソイドワクチン市場規模 フランスの破傷風トキソイドワクチン市場規模 … - アジア太平洋の破傷風トキソイドワクチン市場規模 中国の破傷風トキソイドワクチン市場規模 インドの破傷風トキソイドワクチン市場規模 日本の破傷風トキソイドワクチン市場規模 … - 中東・アフリカの破傷風トキソイドワクチン市場規模 GCC諸国の破傷風トキソイドワクチン市場規模 南アフリカの破傷風トキソイドワクチン市場規模 … - 南米の破傷風トキソイドワクチン市場規模 ブラジルの破傷風トキソイドワクチン市場規模 アルゼンチンの破傷風トキソイドワクチン市場規模 … - その他地域の破傷風トキソイドワクチン市場規模 ・競争状況 ・市場機会・将来の動向 |
The tetanus toxoid vaccine market is expected to register a CAGR of 4.8% during the forecast period (2022-2027).
The tetanus toxoid vaccine market is significantly impacted by COVID-19. According to the study published in the National Institutes of Health in January 2021, “Does tetanus vaccination contribute to reduced severity of the COVID-19 infection?” tetanus vaccination may help to reduce the severity of COVID-19 infection, but more research is needed to confirm or refute the effectiveness of the tetanus toxoid vaccine against COVID-19. Additionally, according to the article published in the Frontier Journal in October 2021, by Jennifer Monereo-Sánchez, vaccination against diphtheria or tetanus is linked to less severe COVID-19 symptoms. By stimulating the immune system, these vaccinations may protect against severe COVID-19 symptoms.
Tetanus, also known as lockjaw disease, is a non-communicable serious disease caused by a bacterial toxin that affects the nervous system, leading to painful muscle contractions, particularly the jaw and neck muscles. It is caused by Clostridium tetani (C. tetani) found in human and animal feces, soil, and street dust. The bacteria enter the body through wounds. Some of the symptoms include lockjaws (paralysis of the jaw), muscle stiffness, back pain, difficulties in breathing, and spasms. Most cases of tetanus occur in people who have never been vaccinated or in adults who have not kept up with their 10-year booster shots. There are different vaccines that include protection against tetanus are DTaP vaccine, DT vaccine, Tdap vaccine, and Td vaccine.
According to the Center For Diseases and Control Prevention in 2021, between 500–600 cases (approximately 0.4 cases per 100,000 population) were reported per year in the United States. As the number of cases has increased in recent years, the market is expected to grow in the coming years.
Rising cases of tetanus and diphtheria, new products under the clinical trials, and increasing government initiatives regarding vaccination and immunization are the key driving factors of the tetanus toxoid vaccine market. For instance, according to the Clinicaltrials. gov in 2020, title”Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects” is under the phase II trials.
Thus, all aforementioned factor such as rising number of cases of tetanus and diphtheria and rising in muber of trials boost the market.
Tetanus Toxoid Vaccine Market Trends
Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Segment is Expected to Hold a Major Market Share in the Tetanus Toxoid Vaccine Market
Diphtheria, tetanus, and pertussis (DTaP) vaccine segment holds a significant market share in the tetanus toxoid vaccine market. It is anticipated to show a similar trend over the forecast period due to the growing government initiatives to eradicate these diseases.
DTaP is a vaccine that helps in developing immunity against three deadly diseases caused by diphtheria, tetanus, and whooping cough (pertussis) in children younger than seven years old.
According to the World Health Organization (WHO) Report in 2022, the total number of Diptheria cases reported in India in 2019 was 9,622, compared to 8,788 in 2018. Similarly, the total number of tetanus is 7,071 is compared to the 7,000 cases in 2018.
According to, the World Health Organization 2021, As of November 11, 2020, five countries in the Region of the Americas had reported a total of 56 confirmed cases of diphtheria, with 16 deaths: Brazil (2 confirmed cases), the Dominican Republic (3 confirmed cases, including 2 deaths), Haiti (42 confirmed cases, including 11 deaths), Peru (4 confirmed cases, including one death), and the Bolivarian Republic of Venezuela (4 confirmed cases, including one death) (5 confirmed cases, including 2 deaths). Thus, rising the prevalence diphtheria rise in diphtheria, tetanus, and pertussis (DTaP) vaccine thereby boost the segment.
Low costs of the vaccine, increasing cases of tetanus, and increasing availability in low resource economies like Africa are the key driving factors in the diphtheria, tetanus, and pertussis (DTaP) vaccine segment.
North America is Expected to Hold a Significant Share in the Market during the Forecast Period
North America is expected to hold a major market share in the global tetanus toxoid vaccine market due to the increasing cases of tetanus and diphtheria and higher cost, high coverage, and adoption in this region. According to the World Health Organization report in May 2019, in the 56 probable cases reported in 2019, 6 cases and 1 death were confirmed by the laboratory. The case-fatality rate among cases confirmed by laboratory or an epidemiological link was 23% in 2015, 39% in 2016, 8% in 2017, 13% in 2018, and 17% in 2019.
Furthermore, as per the same source, the age group of 6 to 14-year-olds has the highest incidence rate among confirmed cases in 2019, followed by 1 to 5-year-olds. A 5-year-old child died as a result of the fatal case. In 2019, the communities of Acul du Nord (3.58 cases per 100,000 population) in the Nord Department and Tabarre (3.07 cases per 100,000 population) in the Ouest Department reported the highest cumulative incidence rate of probable cases.
All tetanus-related deaths occurred among patients greater than 55 years of age. Furthermore, increasing focus to control the incidence and presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.
Thus, all aforementioned factor expected boost the tatanus toxoid vaccine market in the North America region.
Tetanus Toxoid Vaccine Market Competitor Analysis
The tetanus toxoid vaccine market is fragmented, competitive, and consists of several major players. Some of the prominent players that are currently dominating the market are Merck & Co. Inc., GlaxoSmithKline PLC, Sanofi (Sanofi Pasteur Inc.), Pfizer Inc., Bharat Biotech, Astellas Pharma Inc., Panacea Biotec Ltd, BB – NCIPD Ltd, PT Bio Farma, and Biological E Limited.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Cases of Tetanus and Diphtheria in Some Countries
4.2.2 Growing Research and Development Activities for New Vaccines
4.2.3 Increasing Government Initiatives Programs for Vaccination
4.3 Market Restraints
4.3.1 Side-effects Associated with Toxoid Vaccine
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Vaccine Type
5.1.1 Diphtheria, Tetanus, and Pertussis (DTaP)
5.1.2 Diphtheria and Tetanus (DT)
5.1.3 Tetanus, Diphtheria, And Pertussis (Tdap)
5.1.4 Other Vaccines
5.2 By End User
5.2.1 Hospitals and Clinics
5.2.2 Other End Users
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Merck & Co. Inc
6.1.2 GlaxoSmithKline Plc
6.1.3 Sanofi (Sanofi Pasteur Inc.)
6.1.4 Pfizer Inc.
6.1.5 Bharat Biotech
6.1.6 Astellas Pharma Inc.
6.1.7 Panacea Biotec Ltd
6.1.8 BB – NCIPD Ltd
6.1.9 PT Bio Farma
6.1.10 Biological E Limited
7 MARKET OPPORTUNITIES AND FUTURE TRENDS